Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-545

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 68001-545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pemetrexed For Injection 750mg Label (Image 01)

This text is a description of a drug called Pemetrexed, which is for Injection and only to be used intravenously. It comes in a single-dose vial called OncoPoint and each vial contains pemetrexed disodium equivalent to 750 mg pemetrexed, 750 mg of mannitol. It is a Cytotoxic Agent and caution should be taken while handling it. The storage temperature is between 20°C to 25°C (68 to 77°F), and the literature accompanying the drug should be consulted for the storage of reconstituted and infusion solutions. It is manufactured by lnd Phama L, Ind. for BusPont Laboratories.*

FDA Label Image

Pemetrexed For Injection 750mg Carton (Image 02)

FDA Label Image

Structure (Image 03)

FDA Label Image

Figure 1 (Image 04)

FDA Label Image

Figure 2 (Image 05)

This looks like a data table showing survival probabilities and time in months. There are two columns, one titled "Survival Probability" and one titled "Survival Time." The data in the table appears to be numerical values, but without further context or information it's difficult to interpret their meaning.*

FDA Label Image

Figure 3 (Image 06)

This appears to be medical data, likely related to a study or research on a drug combination called Gometabin + Clpi. The rest of the text includes patient IDs and survival time, measured in months. There is no other useful information available.*

FDA Label Image

Figure 4 (Image 07)

FDA Label Image

Figure 5 (Image 08)

This appears to be a graph or chart with data related to "Survival Probability" and "Survival Time (months)". The X-axis shows the time in months, while the Y-axis shows the survival probability. The chart may have additional features or content, but without further context, this is the only information that can be determined from the provided text.*

FDA Label Image

Figure 6 (Image 09)

This appears to be a graph showing survival probability for two groups of patients - one who received "Pometocea" and another who received a "Placebo." The x-axis appears to show survival time in months, while the y-axis shows the proportion of patients who survived up to that time. There are also numbers indicating the number of patients at risk in each group at different time points. No further information can be discerned from the text provided.*

FDA Label Image

Figure 7 (Image 10)

FDA Label Image

Figure 8 (Image 11)

This is a medical report of two groups of patients, one treated with Pematrexed (with 350 patients at the beginning) and the other treated with Placsbo (with 180 patients at the beginning). The report includes the number of patients at risk after a certain period of time (indicated by the numbers at the bottom). There is not enough information to determine the time interval or what "aw" and "2" represent.*

FDA Label Image

Figure 9 (Image 12)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.